Dundee Energy Limited (DEN.TO) 0.25 $DEN.TO
Dundee Energy Limited: Relinquishment of Castor Underground Natural Gas Storage Concession by Escal UGS S.L.
Marketwire - Mon Jul 21, 4:02PM CDT
Dundee Energy Limited ("Dundee Energy" or the "Corporation"
(TSX: DEN) today announced that on July 18, 2014, and following receipt of the necessary consents, Escal UGS S.L. filed an application for the relinquishment of the exploitation concession related to the Castor underground gas storage project with the Spanish Ministry of Industry, Energy and Tourism. Through its subsidiary, Castor UGS Limited Partnership, Dundee Energy effectively holds an indirect 24% interest in Escal UGS S.L.
Dundee Energy Limited Announces Second Quarter 2014 Financial Results
Marketwire - Thu Jul 17, 4:22PM CDT
Dundee Energy Limited ("Dundee Energy" or the "Corporation" (TSX: DEN) today announced its financial results for the three and six months ended June 30, 2014. The Corporation's unaudited condensed interim consolidated financial statements, along with management's discussion and analysis have been filed on the System for Electronic Document Analysis and Retrieval ("SEDAR" and may be viewed under the Corporation's profile at www.sedar.com or the Corporation's website at www.dundee-energy.com.
Windiga Energy to Realize the First Solar Power Plant in Burkina Faso
PR Newswire Europe - Thu Jun 26, 12:01AM CDT
MONTREAL, June 26, 2014 /PRNewswire/ --
/R E P E A T -- Windiga Energy to Realize the First Solar Power Plant in Burkina Faso/
CNW Group - Thu Jun 26, 12:00AM CDT
Windiga Energy, a Canadian-based independent renewable energy power producer, and the Government of Burkina Faso, as represented by Lamoussa Salif KABORE, Minister of Mines and Energy and Lucien Marie Noël BEMBAMBA, Minister of Economy and Finance, have signed an investment support agreement thereby enabling Windiga to become the first independent solar energy producer in the country. Siemens Energy Smart Generation Solutions has been selected to build and operate the pioneering 20-megawatt photovoltaic ("PV" plant, which will be located in Zina, in the Mouhoun province. The facility is scheduled to be completed at the end of 2015 and will be the largest photovoltaic power station in Sub-Saharan Africa. The PV power plant is a project that would include, among its potential financiers, the African Development Bank (AfDB), the Frontier Markets Fund Managers and the Emerging Africa Infrastructure Fund.
Dundee Energy Limited Announces 2013 Financial Results
Marketwire - Mon Mar 17, 5:54PM CDT
Dundee Energy Limited (TSX: DEN) ("Dundee Energy" or the "Corporation" today announced its financial results for the year ended December 31, 2013. The Corporation's annual audited consolidated financial statements, along with management's discussion and analysis, have been filed on the System for Electronic Document Analysis and Retrieval ("SEDAR" and may be viewed under the Corporation's profile at www.sedar.com or the Corporation's website at www.dundee-energy.com.
Global Multiple Sclerosis Drug Forecast and Market Analysis to 2022: Pharma Giants Spending Big to Hold Dominance
M2 - Thu Feb 27, 2:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/sk3tgc/pharmapoint) has announced the addition of the "PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2022 Event-Driven Update" report to their offering. Pharma Giants Spending Big to Hold Dominance in MS Treatment Market The MS market has historically been dominated by four players: Bayer HealthCare, Biogen Idec, Teva, and Merck Serono. These companies have been the leading competitors globally since the 1990s, with the successful launch of Bayer's Betaseron/Betaferon (interferon beta-1b) followed soon after by Biogen's Avonex (interferon beta-1a), Teva's Copaxone (glatiramer acetate) and Merck's Rebif (interferon beta-1a). These established first-line DMTs have shaped the treatment paradigm and now generate the majority of global sales. However, the MS market has become increasingly competitive with the emergence of oral therapies, several pipeline products with notable efficacies, and looming biosimilars following the patent expiries of key branded products. Therefore, these top four companies are facing major challenges in maintaining their position in the MS marketplace, especially with the entry of new challengers onto the competitive landscape. In an attempt to gain market share, companies are seeking to expand the coverage of their existing products to enhance the treated patient population, and are targeting alternative disease subtypes where competition is less fierce. Biogen is investigating Tysabri (natalizumab) for the treatment of secondary-progressive MS, while Novartis' Gilenya (fingolimod) is being evaluated for primary-progressive MS. Another common strategy is to seek approval or brand extensions based on combination therapies. For example, Sanofi/Genzyme's Aubagio (teriflunomide) and Teva's/Active Biotech's laquinimod (ABR-215062) are already being tested as possible adjuvant therapies, which would allow these drugs to generate uptake even if more efficacious drugs are available. Partnerships also allow companies to broaden pipeline portfolios and build experience in target markets. The recent collaborative agreement between Merck and Opexa Therapeutics for the development and commercialization of Tcelna (imilecleucel-T), a novel first-in-class MS vaccine, is of particular strategic importance. Roche/Genentech, with no previous involvement in the MS market, also entered an agreement with Biogen for the development of its late-stage pipeline product, ocrelizumab (RG1594), which will help maximize potential future sales for the drug. In addition, Teva's acquisition of Taiyo Pharmaceutical Industry in 2011 will boost the company's presence in Japan, representing an important opportunity for Teva to extend its MS franchise in future. Estimates that DMT sales for MS across the global markets (US, France, Germany, Italy, Spain, the UK, Japan, Canada, China, and India) will grow from around US$12.6 billion in 2012 to US$13.6 billion in 2022, with a Compound Annual Growth Rate (CAGR) of 0.7%. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix For more information visit http://www.researchandmarkets.com/research/sk...harmapoint
Dundee Energy Limited Announces Director Resignation
Marketwire - Wed Feb 26, 1:41PM CST
Dundee Energy Limited ("Dundee Energy" or the "Company" (TSX: DEN) announces that Ned Goodman has resigned as a director of the Company. The board of directors of Dundee Energy would like to thank Mr. Goodman for his contribution to the Company. Mr. Goodman's replacement will be announced following the next meeting of the Company's board.
Dundee Energy Limited Announces Refinancing Terms for the Castor Project
Marketwire - Fri Jul 26, 1:57PM CDT
Dundee Energy Limited ("Dundee Energy" or the "Corporation" (TSX: DEN) is pleased to announce that Escal UGS S.L. ("Escal" , the owner of the Castor Project, has arranged for the issuance of euro-denominated senior secured bonds (the "Euro Bonds" totalling EUR1.40 billion. The Euro Bonds are subject to an annual interest rate of 5.756%, payable semi-annually, and are repayable in equal semi-annual instalments over a period of 21 and a half years, with the last payment due in December 2034. The Euro Bonds will be listed on the Luxembourg stock exchange.
Dundee Energy Limited Announces Negotiations to Refinance Castor Project
Marketwire - Mon Jul 15, 10:13AM CDT
Dundee Energy Limited ("Dundee Energy" or the "Corporation) (TSX: DEN) announces today that Watercraft Capital S.A., a Luxembourg corporation ("Watercraft" , has been established for the sole purpose of raising approximately EUR1.434 billion 21.5-year secured Euro-denominated bonds (the "Euro Bonds" as a refinancing of the Castor underground gas storage facility in Spain. Proceeds raised from the offering will be on-lent to Escal UGS SL to refinance the Castor Project. The terms and conditions of the Euro Bonds have not been finalized and remain subject to regulatory and other customary approvals.
Dundee Energy Limited: Relinquishment of Castor Underground Natural Gas Storage Concession by Escal UGS S.L.
Marketwire - Mon Jul 21, 4:02PM CDT
Dundee Energy Limited ("Dundee Energy" or the "Corporation"
(TSX: DEN) today announced that on July 18, 2014, and following receipt of the necessary consents, Escal UGS S.L. filed an application for the relinquishment of the exploitation concession related to the Castor underground gas storage project with the Spanish Ministry of Industry, Energy and Tourism. Through its subsidiary, Castor UGS Limited Partnership, Dundee Energy effectively holds an indirect 24% interest in Escal UGS S.L. Dundee Energy Limited Announces Second Quarter 2014 Financial Results
Marketwire - Thu Jul 17, 4:22PM CDT
Dundee Energy Limited ("Dundee Energy" or the "Corporation"
(TSX: DEN) today announced its financial results for the three and six months ended June 30, 2014. The Corporation's unaudited condensed interim consolidated financial statements, along with management's discussion and analysis have been filed on the System for Electronic Document Analysis and Retrieval ("SEDAR" and may be viewed under the Corporation's profile at www.sedar.com or the Corporation's website at www.dundee-energy.com. Windiga Energy to Realize the First Solar Power Plant in Burkina Faso
PR Newswire Europe - Thu Jun 26, 12:01AM CDT
MONTREAL, June 26, 2014 /PRNewswire/ --
/R E P E A T -- Windiga Energy to Realize the First Solar Power Plant in Burkina Faso/
CNW Group - Thu Jun 26, 12:00AM CDT
Windiga Energy, a Canadian-based independent renewable energy power producer, and the Government of Burkina Faso, as represented by Lamoussa Salif KABORE, Minister of Mines and Energy and Lucien Marie Noël BEMBAMBA, Minister of Economy and Finance, have signed an investment support agreement thereby enabling Windiga to become the first independent solar energy producer in the country. Siemens Energy Smart Generation Solutions has been selected to build and operate the pioneering 20-megawatt photovoltaic ("PV"
plant, which will be located in Zina, in the Mouhoun province. The facility is scheduled to be completed at the end of 2015 and will be the largest photovoltaic power station in Sub-Saharan Africa. The PV power plant is a project that would include, among its potential financiers, the African Development Bank (AfDB), the Frontier Markets Fund Managers and the Emerging Africa Infrastructure Fund. Dundee Energy Limited Announces 2013 Financial Results
Marketwire - Mon Mar 17, 5:54PM CDT
Dundee Energy Limited (TSX: DEN) ("Dundee Energy" or the "Corporation"
today announced its financial results for the year ended December 31, 2013. The Corporation's annual audited consolidated financial statements, along with management's discussion and analysis, have been filed on the System for Electronic Document Analysis and Retrieval ("SEDAR" and may be viewed under the Corporation's profile at www.sedar.com or the Corporation's website at www.dundee-energy.com. Global Multiple Sclerosis Drug Forecast and Market Analysis to 2022: Pharma Giants Spending Big to Hold Dominance
M2 - Thu Feb 27, 2:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/sk3tgc/pharmapoint) has announced the addition of the "PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2022 Event-Driven Update" report to their offering. Pharma Giants Spending Big to Hold Dominance in MS Treatment Market The MS market has historically been dominated by four players: Bayer HealthCare, Biogen Idec, Teva, and Merck Serono. These companies have been the leading competitors globally since the 1990s, with the successful launch of Bayer's Betaseron/Betaferon (interferon beta-1b) followed soon after by Biogen's Avonex (interferon beta-1a), Teva's Copaxone (glatiramer acetate) and Merck's Rebif (interferon beta-1a). These established first-line DMTs have shaped the treatment paradigm and now generate the majority of global sales. However, the MS market has become increasingly competitive with the emergence of oral therapies, several pipeline products with notable efficacies, and looming biosimilars following the patent expiries of key branded products. Therefore, these top four companies are facing major challenges in maintaining their position in the MS marketplace, especially with the entry of new challengers onto the competitive landscape. In an attempt to gain market share, companies are seeking to expand the coverage of their existing products to enhance the treated patient population, and are targeting alternative disease subtypes where competition is less fierce. Biogen is investigating Tysabri (natalizumab) for the treatment of secondary-progressive MS, while Novartis' Gilenya (fingolimod) is being evaluated for primary-progressive MS. Another common strategy is to seek approval or brand extensions based on combination therapies. For example, Sanofi/Genzyme's Aubagio (teriflunomide) and Teva's/Active Biotech's laquinimod (ABR-215062) are already being tested as possible adjuvant therapies, which would allow these drugs to generate uptake even if more efficacious drugs are available. Partnerships also allow companies to broaden pipeline portfolios and build experience in target markets. The recent collaborative agreement between Merck and Opexa Therapeutics for the development and commercialization of Tcelna (imilecleucel-T), a novel first-in-class MS vaccine, is of particular strategic importance. Roche/Genentech, with no previous involvement in the MS market, also entered an agreement with Biogen for the development of its late-stage pipeline product, ocrelizumab (RG1594), which will help maximize potential future sales for the drug. In addition, Teva's acquisition of Taiyo Pharmaceutical Industry in 2011 will boost the company's presence in Japan, representing an important opportunity for Teva to extend its MS franchise in future. Estimates that DMT sales for MS across the global markets (US, France, Germany, Italy, Spain, the UK, Japan, Canada, China, and India) will grow from around US$12.6 billion in 2012 to US$13.6 billion in 2022, with a Compound Annual Growth Rate (CAGR) of 0.7%. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix For more information visit http://www.researchandmarkets.com/research/sk...harmapoint
Dundee Energy Limited Announces Director Resignation
Marketwire - Wed Feb 26, 1:41PM CST
Dundee Energy Limited ("Dundee Energy" or the "Company"
(TSX: DEN) announces that Ned Goodman has resigned as a director of the Company. The board of directors of Dundee Energy would like to thank Mr. Goodman for his contribution to the Company. Mr. Goodman's replacement will be announced following the next meeting of the Company's board. Dundee Energy Limited Announces Refinancing Terms for the Castor Project
Marketwire - Fri Jul 26, 1:57PM CDT
Dundee Energy Limited ("Dundee Energy" or the "Corporation"
(TSX: DEN) is pleased to announce that Escal UGS S.L. ("Escal" , the owner of the Castor Project, has arranged for the issuance of euro-denominated senior secured bonds (the "Euro Bonds" totalling EUR1.40 billion. The Euro Bonds are subject to an annual interest rate of 5.756%, payable semi-annually, and are repayable in equal semi-annual instalments over a period of 21 and a half years, with the last payment due in December 2034. The Euro Bonds will be listed on the Luxembourg stock exchange. Dundee Energy Limited Announces Negotiations to Refinance Castor Project
Marketwire - Mon Jul 15, 10:13AM CDT
Dundee Energy Limited ("Dundee Energy" or the "Corporation) (TSX: DEN) announces today that Watercraft Capital S.A., a Luxembourg corporation ("Watercraft"
, has been established for the sole purpose of raising approximately EUR1.434 billion 21.5-year secured Euro-denominated bonds (the "Euro Bonds" as a refinancing of the Castor underground gas storage facility in Spain. Proceeds raised from the offering will be on-lent to Escal UGS SL to refinance the Castor Project. The terms and conditions of the Euro Bonds have not been finalized and remain subject to regulatory and other customary approvals. 
